News

Alimera Sciences Inc., has made available the interim, 12-month safety and efficacy data from the first human pharmacokinetic study of fluocinolone acetonide intravitreal insert (Iluvien), which is currently under development for the treatment of diabetic macular edema, the company said in a prepared statement.

HyperBranch Medical Technology Inc. has granted BD Medical-Ophthalmic Systems, a unit of Becton, Dickinson and Co., an exclusive worldwide license to market its liquid ocular bandage (OcuSeal), according to a prepared statement.

The FDA has accepted for review a supplemental new drug application submitted by Sirion Therapeutics Inc., which seeks market approval of difluprednate ophthalmic emulsion 0.05% (Durezol) for the treatment of endogenous anterior uveitis, according to a statement issued by Sirion.

A lack of access to eye-care services for residents in rural and low-income areas has become a major public health crisis in America, according to analysis from the George Washington University School of Public Health and Health Services.

iScience Interventional has launched a new surgeon support Web site, called iForum, that can be viewed at www.iforummd.com, according to a release issued by the company.

ThromboGenics has completed patient enrollment for a phase II trial of microplasmin intravitreal injection for the treatment of diabetic macular edema, according to a statement issued by the company.

Bausch & Lomb and Santen Pharmaceutical Co. have entered into a licensing agreement for the development of certain IOL materials, according to statements issued by the companies. Financial terms will not be disclosed.

Bausch & Lomb and Pfizer have entered into a co-promotion agreement that involves both companies? prescription ophthalmic pharmaceuticals in the United States, the companies announced in a joint statement.

Alcon announced in a prepared statement that the FDA has approved its aspheric toric IOL (AcrySof).

Roche and Genentech announced that they have signed a merger agreement in which Roche will acquire the outstanding publicly held shares of Genentech for $95 per share, or $46.8 billion, according to statements issued by both companies.

Bausch & Lomb has launched a marketing initiative with the goal of raising U.S. awareness of presbyopia and multi-focal contact lenses.

Beams of light are being used as a less invasive, less expensive approach to spot early stages of retinal damage from diabetic retinopathy by measuring blood flow in the back of the eye, according to scientists in California.

Ophthalmologists looking for a new avenue for growth might want to consider adding bimatoprost ophthalmic solution 0.03% (Latisse, Allergan) to their repertoire.

After following a rigorous clinical comparison of excimer laser platform technologies, LCA Vision is finalizing plans to reduce the number of platforms at each of its LASIKPlus vision centers from three to two.

European Union-Public screenings were scheduled to take place on World Glaucoma day today at a variety of venues including private practices and hospitals in Austria, Belgium, Bulgaria, Greece, Italy, Spain, and Switzerland, in observance of World Glaucoma Day.

Rome-Tiziana Fattori, MD, of Per Vedere Fatti Vedere onlus in Italy explained the reasons behind the launch of a campaign to abolish bureaucratic procedures inhibiting patients from undertaking treatment for glaucoma.

London-In observance of World Glaucoma Day (WGD), the Motion Displacement Test (MDT), developed by Moorfields Eye Hospital, London, in partnership with University College London (UCL) Institute of Ophthalmology and City University London was on display as part of a demonstration of the latest glaucoma diagnostic equipment.

Latin America-World Glaucoma Day events occurred across Latin and Central America. In Argentina, Maria Carrasco, MD, of Hospital Perrupato granted radio interviews about glaucoma in Mendoza. Television, radio, and newspaper interviews also were scheduled in San Pedro, Argentina (Jorge Marceillac, MD), Santa Cruz, and Buenos Aires.

Washington, DC-To recognize the second annual World Glaucoma Day (WGD), the Association for Eye and Vision Research (AEVR) sponsored a March 10 Capitol Hill briefing to educate Members of Congress and their staffs.

New York-As president and chief executive officer of the World Glaucoma Foundation, and president of the World Glaucoma Patient Association (WGPA), Scott R. Christensen has been extensively involved in planning and coordinating efforts around the world to raise awareness about the critical need to detect glaucoma in its earliest stages possible.

United States-Many World Glaucoma Day activities occurred across the United States.

New York-In observance of the second annual World Glaucoma Day, ambassadors, deputy ambassadors, and the secretary general and his staff at the United Nations headquarters here were invited to a free glaucoma screening Wednesday, which was hosted by the New York Eye and Ear Infirmary and The Glaucoma Foundation.

New York-The World Glaucoma Association and the World Glaucoma Patient Association (WGPA) are teaming up with governmental agencies, health-care providers, eye-care industry members, and others to sponsor the second annual World Glaucoma Day (WGD) today, which is expected to surpass last year's efforts.

New York-To help celebrate the second annual World Glaucoma Day, government representatives, eye-care professionals, patient groups, and members of the industry throughout the world offered their support through specific programs designed to increase global awareness of glaucoma and the importance of early detection and successful management.

Diabetes prevalence has doubled in the past decade, and the increases in diabetes-related eye disease poses a new challenge to eye specialists, according to an editorial in the March issue of Archives of Ophthalmology.

Four researchers from Case Western Reserve University Medical School, Cleveland, OH, received a $1.04 million grant to continue their research into diseases including age-related macular degeneration.

PresbyLASIK, an advanced form of LASIK developed to correct presbyopia, may reduce the need for glasses for middle-aged patients, according to research.

San Diego-Intervention can improve patient adherence with once-daily glaucoma therapy, according to results of a randomized clinical trial reported by David S. Friedman, MD, PhD, professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore.